Lifshitz Law PLLC Announces Investigations of Replimune Group, Inc. (NASDAQ: REPL), Datavault AI Inc. (NASDAQ: DVLT), Blaize Holdings, Inc. (NASDAQ: BZAI), and ARS Pharmaceuticals (NASDAQ: SPRY)
Key Highlights
- ➤Replimune (REPL) investigation alleges FDA concerns and incomplete RP1-104 data were not disclosed
- ➤Datavault AI (DVLT) investigation alleges overstated partnership value and minimal platform trading activity
- ➤Blaize (BZAI) investigation alleges sham transactions and improper revenue recognition
- ➤ARS Pharmaceuticals (SPRY) investigation alleges concealed delays to expanded CVS Caremark coverage
NEW YORK CITY, NY / ACCESS Newswire / October 27, 2026 / Lifshitz Law Firm
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose that: (i) in connection with the Biologics License Application ("BLA"), the study design concerns previously communicated by the FDA were not addressed; (ii) Replimune had submitted data from an early unplanned analysis from RP1-104, which included only 40 patients (10% of the planned enrollment of 400 patients); and (iii) as a result, RPL-001-16 and RP1-104 both had deficiencies which were likely to cause the FDA to reject the BLA.
Get started
Create a free account to read the full story.